PCOS Emerging Research and Trials to Watch in 2026
A guide to the latest PCOS research, including GLP-1 receptor agonists, ovasitol, anti-Müllerian hormone diagnostics, and ongoing clinical trials for polycystic ovary syndrome.
Perimenopause Caregiver and Family Resources
Evidence-based guide for caregivers and families supporting someone through perimenopause, covering communication strategies, treatment literacy, mental health support, and clinical resources.
Perimenopause Diagnostic Algorithm: A Step-by-Step Clinical Guide
A step-by-step perimenopause diagnostic algorithm covering STRAW+10 staging, lab workup, differential diagnosis, and treatment initiation based on major society guidelines.
Perimenopause Guidelines Compared: ADA, AACE, Endocrine Society, USPSTF, and NAMS
A side-by-side comparison of major society guidelines for diagnosing and treating perimenopause, including hormone therapy recommendations from NAMS, the Endocrine Society, AACE, and USPSTF.
Perimenopause and Mental Health: Mood, Sleep and Memory
MedlinePlus lists feeling moody, anxious or irritable among menopausal transition symptoms. See what sources say on sleep, memory and hormone therapy.
Perimenopause Nutrition and Lifestyle Protocols
Evidence-based nutrition, exercise, and lifestyle strategies for managing perimenopause symptoms, backed by major society guidelines and clinical trial data.
Post-Surgical Recovery: Caregiver and Family Resources
Evidence-based guide to caregiving after surgery, covering wound care, medication management, nutrition, mobility support, mental health, and when to call the surgeon.
Post-Surgical Recovery Diagnostic Algorithm: A Step-by-Step Clinical Framework
A structured framework for tracking post-surgical recovery across wound healing, pain trajectory, clot risk, nutrition, and function, with guidance on which findings warrant escalation and which reflect normal variation.
Prediabetes Caregiver and Family Resources
Evidence-based guide for caregivers and families supporting someone with prediabetes, including lifestyle strategies, screening recommendations, shared-risk awareness, and practical tools from the ADA, CDC, and major clinical trials.
Guidelines for Prediabetes Management and Diagnosis
ADA criteria: fasting glucose 100-125 mg/dL, A1c 5.7-6.4%, or OGTT 140-199 mg/dL. Screening starts at age 35. See the full diagnostic algorithm.
Prediabetes Exercise Prescription: Evidence-Based Protocols That Lower Your Risk
A guide to exercise protocols for prediabetes, including specific intensity targets, resistance training recommendations, and the trial data behind each prescription.
Management of Prediabetes Guidelines: Treatment Algorithm
Prediabetes management starts with lifestyle changes targeting 7% weight loss, then metformin for high-risk patients, then GLP-1 agonists if obesity persists.
Secondary Hypogonadism: Caregiver and Family Resources
A guide for caregivers and family members supporting someone with secondary hypogonadism, covering diagnosis, treatment options, emotional support strategies, and clinical resources.
Secondary Hypogonadism Guidelines Compared: Endocrine Society, AUA, AACE, ADA, and EAU
A side-by-side comparison of major society guidelines for diagnosing and treating secondary hypogonadism, including diagnostic thresholds, treatment algorithms, and fertility-preserving options.
Secondary Hypogonadism and Mental Health: How Low Testosterone Affects Depression, Anxiety, and Cognition
Low testosterone is linked to depression, but trials show a small mood effect and no memory benefit, and were not designed around secondary hypogonadism.
Tendinopathy and Mental Health: The Overlap Between Chronic Tendon Pain and Psychological Distress
Evidence-based guide on how tendinopathy intersects with depression, anxiety, and sleep disorders, plus integrated treatment strategies backed by clinical research.
Tendinopathy Monitoring Schedule: When to Reassess, What to Track, and When to Escalate
A week-by-week tendinopathy monitoring schedule covering VISA scores, load progression, imaging triggers, and escalation criteria based on current clinical evidence.
Is Type 2 Diabetes Genetic? What Your Family Risk Means
Yes, genetics play a role: one affected parent raises your risk to 40%, but over 400 genes explain only 20% of it. Lifestyle cuts risk 58%.
Type 2 Diabetes Guidelines Compared: ADA vs. AACE vs. Endocrine Society vs. USPSTF
A side-by-side comparison of ADA, AACE, Endocrine Society, and USPSTF guidelines for Type 2 Diabetes diagnosis, A1c targets, first-line therapy, and cardiovascular risk management.
Type 2 Diabetes Nutrition and Lifestyle Protocols
Evidence-based nutrition plans, exercise protocols, and lifestyle changes for managing type 2 diabetes, including ADA and AACE guideline recommendations, macronutrient targets, and meal timing strategies.
Farxiga Generic: Availability, Cost & Alternatives (2026)
Generic dapagliflozin tablets are marketed in the U.S. alongside brand Farxiga. Compare labeled uses and combination products.
Farxiga (Dapagliflozin) Missed-Dose Protocol: What to Do and When to Skip
Evidence-based guide to handling a missed dose of Farxiga (dapagliflozin). Covers timing rules, pharmacokinetics, clinical context for type 2 diabetes, heart failure, and CKD indications, plus what requires a call to your prescriber.
Dapagliflozin Metabolism: UGT1A9 and CYP Role in Farxiga Label
Dapagliflozin is metabolized mainly by UGT1A9, not CYP enzymes, and the Farxiga label has no genotype-based dosing.
Farxiga Pharmacokinetics (ADME): How Dapagliflozin Is Absorbed, Distributed, Metabolized, and Eliminated
A clinician-grade breakdown of dapagliflozin (Farxiga) pharmacokinetics covering absorption, distribution, metabolism, excretion, and real-world dosing implications backed by FDA label data and primary literature.
Dapagliflozin Renal Dose: eGFR Thresholds Explained
Dapagliflozin stays at 10 mg daily regardless of kidney function. Starts at eGFR ≥25; continue until dialysis or transplant. DAPA-CKD data included.
Does Farxiga Cause Bladder Cancer? FDA Findings
The current Farxiga label has no bladder cancer warning; its warnings cover ketoacidosis, volume depletion, genitourinary infections and hypoglycemia.
How to Safely Stop Prolia (Denosumab): Discontinuation Protocol
A guide to safely discontinuing Prolia (denosumab), including bisphosphonate bridging protocols, rebound fracture risks, bone turnover monitoring, and step-by-step transition timelines.
Late Prolia Injection: Catch-Up Dates, Fracture Evidence and Next Steps
A late Prolia dose resets the next six-month date. Use an injection-record worksheet and compare the actual delay and fracture evidence.
Prolia (Denosumab) Monitoring Schedule: Labs & Exams
Complete monitoring schedule for Prolia (denosumab), including baseline labs, calcium checks, DEXA timing, and adverse-effect screening, with PubMed-cited evidence.
Prolia (Denosumab) Patent Status and Generic Timeline
A clinical review of the denosumab (Prolia/Xgeva) patent portfolio, biosimilar development pipeline, FDA regulatory pathway, and projected generic availability dates for patients and prescribers.
Is Low Libido a Warning Sign? Understanding the Canary in the Coal Mine and How to Restore Your Vital Energy
Low libido can signal testosterone deficiency, cardiovascular disease, diabetes, or depression. Learn what declining sex drive really means and evidence-based ways to restore it.
What Is a Longevity Program? A Complete Guide
A longevity program combines biomarker testing, metabolic optimization, hormone therapy, and targeted pharmaceuticals to extend healthspan. This guide covers the evidence, components, costs, and who benefits most.
What PCOS Actually Feels Like: Understanding the Symptoms and Solutions
PCOS causes irregular periods, acne, hair loss, weight gain, and mood changes. Learn what polycystic ovary syndrome really feels like day to day and which treatments work.
Trulicity (Dulaglutide) Adult Dosing: Complete Guide for Ages 30 to 49
Evidence-based Trulicity (dulaglutide) dosing guide for adults aged 30, 49 with type 2 diabetes. Covers starting dose, titration schedule, injection technique, missed-dose rules, and real-world clinical considerations.
Trulicity (Dulaglutide) Safety in Adults Aged 30 to 49: What the Evidence Shows
A guide to dulaglutide (Trulicity) safety for adults aged 30 to 49, covering GI side effects, cardiovascular data from REWIND, pancreatitis risk, thyroid warnings, and practical monitoring advice.
Trulicity (Dulaglutide) Food & Supplement Interactions: What to Eat, Avoid, and Monitor
Evidence-based guide to dulaglutide (Trulicity) food and supplement interactions, including effects on nutrient absorption, alcohol, fiber, and common vitamins.
Trulicity (Dulaglutide) Dosing in Hepatic Impairment
Evidence-based guide to dulaglutide (Trulicity) dosing in patients with hepatic impairment, including pharmacokinetic data, clinical recommendations, and liver safety monitoring.
Trulicity Missed-Dose Protocol: What to Do When You Skip a Dulaglutide Injection
Evidence-based protocol for managing a missed Trulicity (dulaglutide) dose, including timing thresholds, double-dose risks, and how to get back on schedule safely.
Trulicity (Dulaglutide) Patent Status & Generic Timeline: What to Expect
A clinical review of dulaglutide (Trulicity) patent filings, exclusivity windows, biosimilar development, and projected generic availability for patients with type 2 diabetes.
Trulicity (Dulaglutide) Real-World Evidence: What Registries and RWE Studies Actually Show
A physician-level review of dulaglutide (Trulicity) real-world evidence from registries, claims databases, and post-marketing studies, including REWIND cardiovascular data and adherence outcomes.
Trulicity (Dulaglutide) Dosing in Renal Impairment: What the Evidence Actually Shows
Evidence-based guide to dulaglutide (Trulicity) dosing across all stages of renal impairment, including CKD stages 3-5 and dialysis, with FDA label data, REWIND renal outcomes, and AWARD trial pharmacokinetics.
Trulicity (Dulaglutide) Safety Signals and FDA Actions: What Patients and Clinicians Need to Know
A comprehensive review of dulaglutide (Trulicity) safety signals, FDA regulatory actions, boxed warnings, postmarketing surveillance findings, and clinical trial safety data from REWIND and AWARD trials.
How to Self-Inject Trulicity (Dulaglutide): Step-by-Step Technique, Tips, and Troubleshooting
A guide to Trulicity (dulaglutide) self-injection technique, covering pen anatomy, site selection, injection steps, needle-free design, and how to avoid common errors.
Trulicity (Dulaglutide) in Special Populations: Transplant, HIV, and Beyond
Evidence-based guide to using dulaglutide (Trulicity) in transplant recipients, people living with HIV, older adults, and other special populations. Includes dosing, safety data, and clinical considerations.
Does TRICARE Cover Trulicity? Formulary Tier, Prior Authorization, and Appeal Steps
TRICARE covers Trulicity (dulaglutide) for type 2 diabetes with prior authorization. Learn the formulary tier, step therapy rules, PA criteria, appeal process, and out-of-pocket costs for military beneficiaries.
Dutasteride (Avodart) Monitoring for Adults Ages 30 to 49
Evidence-based monitoring guide for dutasteride (Avodart) in adults aged 30-49, covering PSA adjustments, liver function, hormonal panels, and safety labs for BPH and hair loss.
Stopping Dutasteride: Follow-Up After the Last Dose
Stopping dutasteride: what to record about urinary symptoms, PSA, hair changes and sexual effects, plus the six-month blood donation wait.
Dutasteride (Avodart) Food & Supplement Interactions: What to Avoid and Why
Evidence-based guide to dutasteride food and supplement interactions, including saw palmetto, St. John's wort, grapefruit, and fat-soluble vitamin concerns.
Does State Medicaid Cover Avodart (Dutasteride)? Coverage, Prior Authorization, and Appeals
State Medicaid coverage for Avodart (dutasteride) varies widely. Learn formulary status, prior authorization requirements, step therapy rules, and how to appeal a denial.
Dutasteride (Avodart) Missed-Dose Protocol: What to Do and Why It Matters Less Than You Think
Evidence-based guide to handling a missed dose of dutasteride (Avodart). Covers pharmacokinetics, the 5-week half-life advantage, clinical impact, and step-by-step instructions.
Dutasteride (Avodart) Monitoring Schedule: Labs, Exams, and Follow-Up Timeline
Evidence-based monitoring schedule for dutasteride (Avodart), including baseline labs, PSA adjustments, liver function testing, and follow-up exam intervals for BPH and hair loss.
Dutasteride Half-Life 5 Weeks: FDA Dosing Info
Dutasteride's half-life is 5 weeks at steady state, the longest of any 5-alpha reductase inhibitor. FDA dose is 0.5 mg daily, no age adjustment needed.
Avodart Patent History and Generic Dutasteride Timeline
A detailed look at dutasteride (Avodart) patent expiry dates, Paragraph IV challenges, generic approvals, and what the post-exclusivity market means for BPH and hair loss patients.
Dutasteride Pharmacogenomics: How Genetic Variability Shapes Avodart Response
A clinical deep-dive into how CYP3A4, SRD5A1, SRD5A2, and androgen receptor gene polymorphisms influence dutasteride metabolism, efficacy, and side-effect risk.
Avodart Pharmacokinetics (ADME): How Dutasteride Is Absorbed, Distributed, Metabolized, and Eliminated
A clinical deep-dive into dutasteride (Avodart) pharmacokinetics covering absorption, distribution, metabolism, elimination, its 5-week half-life, CYP3A4 metabolism, and DHT suppression kinetics.
Avodart (Dutasteride) Regulatory Status: US, EU, Canada, and UK Approval History
A clinician-level review of dutasteride (Avodart) regulatory approvals across the US, EU, Canada, and UK, including BPH indications, off-label hair loss use, and key differences between jurisdictions.
Dutasteride (Avodart) Safety Signals and FDA Actions: What the Evidence Shows
A clinician-grade review of dutasteride (Avodart) safety signals, FDA label changes, the REDUCE trial prostate cancer finding, sexual adverse effects, and mental health concerns, with PubMed-cited evidence.
Does UnitedHealthcare Cover Avodart (Dutasteride)?
UnitedHealthcare typically covers Avodart (dutasteride) on Tier 3 with prior authorization for BPH. Learn formulary placement, PA criteria, step therapy rules, appeal steps, and cost-saving alternatives.
Jardiance (Empagliflozin) Monitoring in Adults 65 and Older
Evidence-based monitoring guide for empagliflozin (Jardiance) in geriatric patients 65+, covering renal function, volume status, ketoacidosis screening, and deprescribing considerations.
Empagliflozin Dose: Adults 50-64 Need No Age Adjustment
Standard empagliflozin dose is 10 mg daily, up to 25 mg for T2D. Heart failure and CKD stay fixed at 10 mg; renal function guides dosing, not age.